Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV9104 in Metastatic Castrate-Refractory Prostate Cancer
NCT01817738Phase 2Terminated
- Sponsor
- CureVac
- Start
- Aug 2012
- Primary completion
- Aug 2016
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 8
01
Overview
A Phase 2 trial of CV9104 in prostate cancer (PCa), sponsored by CureVac. Started Aug 2012; status: terminated.
02
Drugs
CV9104
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01817738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01817738.